| | SLO | ENG | Cookies and privacy

Bigger font | Smaller font

Show document Help

Title:Encim telomeraza - tarča za prihodnja zdravila?
Authors:ID Langerholc, Tomaž (Author)
Files:.pdf Zdravniski_vestnik_2012_Langerholc_Encim_telomeraza_–_tarca_za_prihodnja_zdravila.pdf (549,45 KB)
MD5: 7EDE088CCAD50DD3FBA6F1765F437C9A
 
URL http://vestnik.szd.si/index.php/ZdravVest/article/view/807
 
Language:Slovenian
Work type:Scientific work
Typology:1.02 - Review Article
Organization:FKBV - Faculty of Agriculture and Life Sciences
Abstract:Problem pomnoževanja koncev evkariontskih kromosomov (telomer) so uspešno rešili z odkritjem encima telomeraze konec 80. let prejšnjega stoletja, za odkritje so leta 2009 podelili tudi Nobelovo nagrado za medicino in fiziologijo. Izražanje telomeraze pri rakavih boleznih in človeške sanje o večni mladosti so močno pospešile razvoj farmakoloških telomeraznih inhibitorjev in aktivatorjev, vendar pa kljub 15-letnemu raziskovanju zdravila še niso dostopna na trgu. V članku smo glede na podatke v svetovnih medijih in literaturi naredili pregled farmakoloških učinkovin v zgodnjih fazah kliničnih preskušanj, ki specifično uravnavajo aktivnost telomeraze. Načrtovana protitumorska zdravila večinoma ne bodo namenjena samostojni uporabi, saj telomerazne inhibitorje klinično preskušajo v kombinaciji z obstoječimi kemoterapevtskimi sredstvi, protitelomerazna cepiva pa v kombinaciji z imunostimulansi. Poleg raka in staranja v prispevku navajamo ostala bolezenska stanja, ki so povezana s telomerazo/telomerami, hkrati pa opisujemo tudi tehnično-pravne probleme pri razvoju novih zdravil. Glede na dinamiko razvoja lahko prva protitelomerazna zdravila na trgu pričakujemo v naslednjih petih letih.
Keywords:telomeraza, imetelstat, cepivo, tumor, rak
Publication status:Published
Publication version:Version of Record
Year of publishing:2012
Number of pages:str. 493-499
Numbering:Letn. 81, št. 6
PID:20.500.12556/DKUM-65285 New window
ISSN:1318-0347
UDC:577:616-006-085
ISSN on article:1318-0347
COBISS.SI-ID:263303936 New window
NUK URN:URN:SI:UM:DK:WJRNYN1D
Publication date in DKUM:28.03.2017
Views:2154
Downloads:132
Metadata:XML DC-XML DC-RDF
Categories:Misc.
:
Copy citation
  
Average score:(0 votes)
Your score:Voting is allowed only for logged in users.
Share:Bookmark and Share



Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Zdravniški vestnik. glasilo Slovenskega zdravniškega društva
Publisher:Slovensko zdravniško društvo
ISSN:1318-0347
COBISS.SI-ID:32893696 New window

Licences

License:CC BY-NC 4.0, Creative Commons Attribution-NonCommercial 4.0 International
Link:http://creativecommons.org/licenses/by-nc/4.0/
Description:A creative commons license that bans commercial use, but the users don’t have to license their derivative works on the same terms.
Licensing start date:28.03.2017

Secondary language

Language:English
Title:Telomerase - future drug target enzyme?
Abstract:Eucaryotic chromosome endings (telomeres) replication problem was solved in the 1980's by discovery of the telomerase enzyme. The Nobel Prize in Physiology or Medicine was awarded in 2009 for the discovery of telomerase. Altered telomerase expression in cancer, and human dream of eternal youth haveaccelerated the development of pharmacological telomerase inhibitors and activators. However, after 15 years of development they are still not available on the market. In the present article we reviewed pharmacological agents that target telomerase activity, which have entered clinical trials. Current drugs in development are mostly not intended to be used alone, as telomerase inhibitors under clinical trials are used in combination with the existing chemotherapeutics and anti-telomerase vaccines in combination with immuno-stimulants. Apart from cancer and aging, there are other diseases linked to deregulated activity of telomerasežtelomeres and we also discuss technical and legal problems that researchers encounter in developing anti-telomerase therapy. Given the pace of development, first anti-telomerase drugs might appear on the market in the next 5 years.
Keywords:telomerase, imetelstat, tumor, cancer, treatment


Comments

Leave comment

You must log in to leave a comment.

Comments (0)
0 - 0 / 0
 
There are no comments!

Back
Logos of partners University of Maribor University of Ljubljana University of Primorska University of Nova Gorica